Zentalis Q1 net loss narrows as operating expenses fall

Zentalis Pharmaceuticals

12/05/2026 22:36

Overview

US oncology drug developer's Q1 net loss narrowed yr/yr as operating expenses declined

Company advanced azenosertib pivotal and confirmatory trials for Cyclin E1-positive ovarian cancer

Cash position was $211.8 mln at March 31, 2026, providing runway into late 2027

Outlook

Company expects DENALI Phase 2 topline readout by year-end 2026

ASPENOVA Phase 3 trial initiated to support full approval and ex-US registrations

Company says cash position expected to fund operations into late 2027

Result Drivers

CLINICAL TRIAL ADVANCEMENT - Higher R&D expenses in Q1 driven by increased clinical and manufacturing costs related to DENALI and ASPENOVA trials

OPERATING EXPENSE DECREASE - Total operating expenses fell yr/yr due to non-recurring restructuring charge in Q1 2025

PRE-COMMERCIAL PREPARATION - Co initiated pre-commercial launch activities, including scaling manufacturing and advancing companion diagnostic market development

Company press release: ID:nGNX5MmTmY

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.50


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $5.50, about 28.5% above its May 12 closing price of $4.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)